High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors. |
| |
| Authors: | M. P. Lyttelton E. S. Newlands C. Giles M. Bower A. Guimaraes S. O'Reilly G. J. Rustin D. Samson E. J. Kanfer |
| |
| Affiliation: | Department of Haematology, Imperial College School of Medicine, Hammersmith Hospitals NHS Trust, London, UK. |
| |
| Abstract: | Thirty-one consecutive patients with relapsed or refractory GCT received an HDT schedule including carboplatin, the dose of which was adjusted to measured glomerular filtration rate. There was one HDT-associated death (3%), due to acute renal failure. The 3-year probability of overall and disease-free survival for 21 patients with primary refractory disease or responsive relapse was 60% and 42%, respectively, while none of ten patients with refractory relapse have survived disease free. |
| |
| Keywords: | |
|
|
